Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
Publication
, Journal Article
Fangusaro, JR; Onar-Thomas, A; Poussaint, TY; Wu, S; Ligon, AH; Lindeman, NI; Banerjee, A; Packer, R; Kilburn, LB; Pollack, IF; Qaddoumi, IA ...
Published in: Neuro Oncol
August 1, 2022
Duke Scholars
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
August 1, 2022
Volume
24
Issue
8
Start / End Page
1404
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Fangusaro, J. R., Onar-Thomas, A., Poussaint, T. Y., Wu, S., Ligon, A. H., Lindeman, N. I., … Dunkel, I. J. (2022). Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol, 24(8), 1404. https://doi.org/10.1093/neuonc/noac029
Fangusaro, Jason R., Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H. Ligon, Neal Ian Lindeman, Anuradha Banerjee, et al. “Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.” Neuro Oncol 24, no. 8 (August 1, 2022): 1404. https://doi.org/10.1093/neuonc/noac029.
Fangusaro JR, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman NI, et al. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol. 2022 Aug 1;24(8):1404.
Fangusaro, Jason R., et al. “Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.” Neuro Oncol, vol. 24, no. 8, Aug. 2022, p. 1404. Pubmed, doi:10.1093/neuonc/noac029.
Fangusaro JR, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman NI, Banerjee A, Packer R, Kilburn LB, Pollack IF, Qaddoumi IA, Fisher PG, Dhall G, Baxter PA, Kreissman SG, Doyle LA, Smith MA, Fouladi M, Dunkel IJ. Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study. Neuro Oncol. 2022 Aug 1;24(8):1404.
Published In
Neuro Oncol
DOI
EISSN
1523-5866
Publication Date
August 1, 2022
Volume
24
Issue
8
Start / End Page
1404
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences